Incremental Effectiveness, Costs May Improve Using Biomarker-Guided Selection
Biomarker-guided selection for nivolumab in MSS/pMMR mCRC could reduce costs and improve efficacy, with lower ICERs in subgroups like those with TMB > 8.0 mut/MB, C-reactive protein < 5.0 mg/L, or target lesion reduction ≥ 10%. This approach could make nivolumab cost-effective in Norway, though validation is needed.
Reference News
Incremental Effectiveness, Costs May Improve Using Biomarker-Guided Selection
Biomarker-guided selection for nivolumab in MSS/pMMR mCRC could reduce costs and improve efficacy, with lower ICERs in subgroups like those with TMB > 8.0 mut/MB, C-reactive protein < 5.0 mg/L, or target lesion reduction ≥ 10%. This approach could make nivolumab cost-effective in Norway, though validation is needed.